首页> 外文期刊>Oncology: International Journal of Cancer Research and Treatment >A pilot study on intensive weekly 24-hour intra-arterial infusion with 5-fluorouracil and folinic acid for colorectal liver metastases.
【24h】

A pilot study on intensive weekly 24-hour intra-arterial infusion with 5-fluorouracil and folinic acid for colorectal liver metastases.

机译:每周24小时密集输注5-氟尿嘧啶和亚叶酸治疗大肠肝转移的初步研究。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: A pilot study was performed to evaluate the tolerance and efficacy of a hepatic arterial infusion (HAI) of 5-fluorouracil (5-FU) and folinic acid (FA) in patients with unresectable liver metastases from colorectal carcinoma. PATIENTS AND METHODS: In 11 patients, 135 applications of high-dose HAI of 5-FU/FA were administered. All patients had been intra-arterially pretreated, and 2 of them had received an additional intravenous therapy. The chemotherapy regimen consisted of a weekly HAI of FA 500 mg/m2 over 1 h, immediately followed by HAI of 5-FU over 24 h. Four patients received a 5-FU starting dose of 2,000 mg/m2 and 7 patients of 2,400 mg/m2. One course consisted of 12 weekly applications interrupted by 1 week after 6 applications and 4 weeks after 12 applications. RESULTS: The applied regimen caused only mild side effects. Nausea and vomiting were the most frequently side effects with 36 episodes out of 135 applications (WHO grade > or = 3: 2 episodes). Diarrhea was a minor problem occurring with 8 episodes (WHO grade > or = 3: 1 episode). There was no evidence of myelosuppression, hand-foot syndrome, neurotoxicity, and biliary sclerosis. A partial remission was observed in 3 patients, and a disease stabilization in 2 patients while the disease progressed in 6 patients under high-dose HAI of 5-FU/FA. CONCLUSION: The present pilot study demonstrates that the weekly high-dose HAI of 5-FU/FA is well tolerated and associated with very mild toxicity. Because of the encouraging response rate in patients, whose disease progressed under the conventional intra-arterial therapy either with 5-FU/FA or 5-fluorodeoxyuridine, this regimen seems to be an effective second-line treatment and should be evaluated in nonpretreated patients in a phase II study.
机译:目的:进行了一项初步研究,以评估5-氟尿嘧啶(5-FU)和亚叶酸(FA)的肝动脉输注(HAI)在结直肠癌无法切除的肝转移患者中的耐受性和疗效。患者与方法:11例患者接受了135次5-FU / FA大剂量HAI的应用。所有患者均接受了动脉内预处理,其中2位接受了额外的静脉治疗。化疗方案包括在1小时内每周一次HAI 500 mg / m2 HAI,然后在24小时内立即进行5-FU HAI。 4名患者接受5-FU起始剂量为2,000 mg / m2,7名患者接受2,400 mg / m2。一门课程包括12周的申请,在6次申请后中断1周,在12次申请后中断4周。结果:所应用的方案仅引起轻微的副作用。恶心和呕吐是最常见的副作用,在135次应用中有36次发作(WHO评分>或= 3:2次发作)。腹泻是一个小问题,有8次发作(WHO评分>或= 3:1次发作)。没有证据表明骨髓抑制,手足综合症,神经毒性和胆道硬化。在5-FU / FA的大剂量HAI下,3例患者部分缓解,2例患者疾病稳定,6例患者疾病进展。结论:目前的初步研究表明,每周对5-FU / FA的高剂量HAI具有良好的耐受性,并具有非常轻微的毒性。由于患者的反应率令人鼓舞,在常规动脉内用5-FU / FA或5-氟脱氧尿苷进行治疗的情况下,疾病进展,因此该方案似乎是有效的二线治疗,应在未接受治疗的患者中进行评估II期研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号